Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs Sana Biotechnology Inc — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $19.42 (market cap $8.95B), while Sana Biotechnology Inc trades at $3.17 (market cap $873.84M). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 10.2× Sana Biotechnology Inc's market cap, and Norwegian Cruise Line Holdings Ltd is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| NCLH | SANA | |
|---|---|---|
Market Cap | $8.95B | $873.84M |
Sector | Consumer Cyclical | Health |
52-Week High | $26.94 | $5.92 |
52-Week Low | $14.79 | $2.68 |
Enterprise Value | $23.92B | $848.03M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NCLH trades at $19.45, down slightly by 0.05%, with a neutral technical signal and bearish moving averages. The company reported revenue of $9.83B in 2025, with net income of $423.25M and a profit margin of 4.3%. Recent quarters show consistent earnings beats, including Q1 2026 EPS of $0.23 versus $0.15 expected. Analyst consensus is bullish with a $20.82 price target, and cash flow trends improved to a positive net of $19M in 2025.
The outlook for NCLH is cautiously optimistic, supported by earnings momentum and analyst buy ratings, but risks include high debt levels and macroeconomic sensitivity. Investment opportunity lies in continued operational recovery and potential upside to price targets, while volatility from fuel costs and travel demand poses challenges.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
